about
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSNo Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.[Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients.ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma.Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerLocal control and survival in patients with soft tissue sarcomas treated with limb sparing surgery in combination with interstitial brachytherapy and external radiation.Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer.Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.Employment and sick leave in patients with prostate cancer before, during and after radiotherapy.(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients.Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.NI-56FET-PET ADDS PREDICTIVE VALUE TO LOCALIZATION OF TREATMENT FAILURE IN HIGH GRADE GLIOMAS.RT-10DO WE NEED IMAGE-GUIDANCE OF GTV DEFINED BY FET-PET IN RADIOTHERAPY OF HIGH GRADE GLIOMA?Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort.Survival outcomes in patients with cervical cancer after inclusion of PET/CT in staging procedures.Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking.RT-22MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL.Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial.Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer.In vivo dose verification of IMRT treated head and neck cancer patients.Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.Positron emission tomography/computed tomography in the staging and treatment of anal cancer.
P50
Q28584533-5D9EE0AC-A533-4F98-B49E-FD8390B59D1EQ30275832-5B336F17-FA3C-4081-A520-FAA8E564002DQ30940235-BB647A83-EB61-40D6-9D21-B290EF081948Q33295365-4BC729AB-ABDB-4574-B474-40C82FB77F58Q33461489-916B251C-2AD1-48C3-AA64-A5ECD02A7A07Q33764466-39053264-E57B-421A-B5A4-27077AC4A9B2Q33947899-76FEB83E-8CF2-473E-A597-6C2A6118DAE5Q33998256-C50F53EA-7173-400C-8864-640A89F24374Q35788602-795D5473-80A6-41D4-B1A1-E74347795FD7Q36335296-62A3E536-1F30-4265-866D-3222011829DAQ36897003-797D27D3-F305-4058-8095-FC24027C9ED0Q36916243-7B7E6220-2A1E-4498-82D0-E528E4B87595Q37201669-3B235D52-7B51-4A1F-8DCB-BC7220ED0691Q37240224-A59B96E3-CE19-4FCE-92C8-27EBFA189145Q37580538-6760BA47-050E-49C1-A81C-B4B28E9331FAQ38418282-F579ED56-4C7D-4A74-A7A8-648978C65146Q39578795-A686A7A4-D2EB-4970-8497-C9BE110EAA15Q39848816-D1E297DE-DB2A-4AC1-AA5F-5A1065F921AEQ40120521-72CDFBD0-9743-4FAA-AD96-8C459E243A3CQ42052373-407476A5-B598-4E08-8913-60E5DB4CD0FAQ42907283-14C008A9-BD82-443D-A4C9-6BE382237408Q44129217-6B88525A-7E65-4B8E-84DD-B22843F6B0C5Q44619361-1302349C-20E0-47A0-B160-43DCC1CD0164Q44968621-DA26058D-8F3A-4360-80D3-13D439BB7BF2Q45009001-B519E5B3-B937-4879-97CA-D8A3448A92F9Q45057186-BC6B159B-90D7-46D2-BAD4-2A9C06684835Q45976010-3BAADC54-6B68-4A4C-819B-4C045CA25E39Q46070882-D875741F-548A-4F60-AB25-2FAAD4518C8DQ46505590-68A5E902-1D85-4EC6-9673-37D1945C0CFFQ47336919-10EC5C9C-E86C-4527-9633-056242FF7D54Q48358805-4AF7B673-855B-4206-86B6-773205A9AD6BQ48985900-A76ADB58-8912-4CE8-99BD-F97F0A8B5644Q49037053-5583173D-0CD7-4053-989D-1998FDED4636Q49194789-AB4B0B7B-D791-4269-93B7-999D83C57F25Q50062139-D7821D9E-6942-44CE-9C3B-83896CD9D552Q50544321-55F5A3C6-5A73-4217-BB15-CA1B809D56EFQ50695478-BD18F5D9-420C-40FF-9630-1163A1F9A3B1Q51354213-F7F6FF6A-614C-4FDE-A870-DBDF70B33E74Q53189037-683CED89-DEFD-4AC3-B494-EFDAFA18CBABQ53196808-C187C9D9-571C-4255-B61B-CBEBADFB9CDE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Svend Aage Engelholm
@ast
Svend Aage Engelholm
@en
Svend Aage Engelholm
@es
Svend Aage Engelholm
@nl
Svend Aage Engelholm
@sl
type
label
Svend Aage Engelholm
@ast
Svend Aage Engelholm
@en
Svend Aage Engelholm
@es
Svend Aage Engelholm
@nl
Svend Aage Engelholm
@sl
prefLabel
Svend Aage Engelholm
@ast
Svend Aage Engelholm
@en
Svend Aage Engelholm
@es
Svend Aage Engelholm
@nl
Svend Aage Engelholm
@sl
P106
P108
P21
P31
P496
0000-0002-9663-9292